The EPS miss is negligible. The stock will be driven by upcoming catalysts: complete Phase 1/2 lupus/scleroderma data at EULAR (June 3-6) and initial PC-free lupus data expected in 1H26. The $150M financing removes near-term dilution risk. Monitor EULAR presentations for signs of efficacy and safety that could de-risk the pivotal program.
Price Chart
Executive Summary
Cabaletta Bio reported Q1 2026 EPS of -$0.40, a 3.1% miss vs consensus of -$0.39, with no revenue. The miss is marginal and typical for a pre-commercial biotech. The key positive is the $150M oversubscribed financing closed in May 2026, extending the cash runway into mid-2027, and encouraging PC-free clinical data from the RESET-PV study presented at ASGCT. The stock is likely to trade on pipeline catalysts (EULAR data in June, lupus data in 2H26) rather than the minor EPS miss.
Key Financial Metrics
Key Facts
- Q1 2026 EPS of -$0.40 vs consensus -$0.39 (3.1% miss)
- No revenue reported (pre-commercial stage)
- Cash, cash equivalents and short-term investments of $116.6M as of March 31, 2026
- Closed $150M registered direct offering in May 2026, extending cash runway into mid-2027
- PC-free clinical data from lowest-dose RESET-PV cohort presented at ASGCT 2026 showing compelling drug-free responses in half of patients at 6 months
- Complete Phase 1/2 lupus and scleroderma data to be presented at EULAR Congress June 3-6, 2026
- Pivotal RESET-Myositis cohort progressing toward first BLA submission planned for 2027
- 10-year commercial supply agreement with Cellares for automated manufacturing
Financial Impact
EPS miss of $0.01 per share is immaterial for a pre-revenue biotech; $150M capital raise is the dominant financial event
Risk Factors
- Clinical trial failure or disappointing efficacy/safety data at EULAR or in upcoming PC-free cohorts
- Regulatory delays or negative FDA feedback on BLA pathway for myositis
- Cash burn rate may require additional financing before mid-2027 if milestones slip
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3294776 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 14, 2026 18d ago | 8-K | $2.91 $2.46 | ▼ −15.46% | ▼ −15.57% | $1.91 (−34.36%) |
Aug 15, 2026 6w ago | Institutional Cluster | $2.89 $3.10 | ▲ +7.27% | ▲ +8.46% | $1.91 (−33.91%) |
Aug 13, 2026 7w ago | 8-K | $2.71 $3.19 | ▲ +17.71% | ▲ +19.68% | $1.91 (−29.52%) |
Aug 13, 2026 7w ago | Press Release | $2.71 $3.19 | ▲ +17.71% | ▲ +19.68% | $1.91 (−29.52%) |
Jun 11, 2026 16w ago | Institutional Cluster | $3.01 $2.84 | ▼ −5.65% | ▼ −6.32% | $1.91 (−36.54%) |
Jun 3, 2026 17w ago | 8-K | $3.58 $3.04 | ▼ −15.08% | ▼ −11.26% | $1.91 (−46.65%) |
Jun 1, 2026 17w ago | DEFA14A | $3.67 $3.25 | ▼ −11.44% | ▼ −8.69% | $1.91 (−47.96%) |
May 14, 2026 20w ago | 8-K | $3.61 $3.69 | ▼ −2.22% | ▼ −2.93% | $1.91 (+47.09%) |
May 14, 2026 20w ago | Press Release | $3.61 $3.69 | ▲ +2.22% | ▲ +2.93% | $1.91 (−47.09%) |
May 14, 2026 20w ago | 8-K | $3.61 $3.69 | ▲ +2.22% | ▲ +2.93% | $1.91 (−47.09%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access